Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
<p>PK profile for EnaV and MMAE in the dose-escalation phase. Plasma/serum concentrations of (<b>A</b>) conjugated EnaV and (<b>B</b>) MMAE at Q3W. Dots indicate observed data; lines indicate mean data. LLOQ, lower limit of quantitation.</p>
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Publicado: |
2025
|
| Materias: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | <p>PK profile for EnaV and MMAE in the dose-escalation phase. Plasma/serum concentrations of (<b>A</b>) conjugated EnaV and (<b>B</b>) MMAE at Q3W. Dots indicate observed data; lines indicate mean data. LLOQ, lower limit of quantitation.</p> |
|---|